EN DE
Data-driven stock valuation

TransThera Sciences (Nanjing) (2617) fair value: what the stock is really worth

We calculate from audited financials what TransThera Sciences (Nanjing) is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.

  1. Compare price with fair valuebelow fair value = cheap, above = expensive
  2. Check the quality50 and up solid, 75 and up strong
  3. Watch it or check another stockalert when fair value or trend changes

Healthcare · HK · Market cap HK$5.1B (≈ $654M)

At a glance

TS TransThera Sciences (Nanjing) 2617 · HK
PriceHK$9.46
Fair ValueHK$1.12
Upside−88.2%
Quality44/100

Below-average quality, and trading another 745% above our fair value of HK$1.12.

As of Sep 11, 2026, the fair value of TransThera Sciences (Nanjing) is HK$1.12 per share against a price of HK$9.46, so the fair value sits 88% below the price. A model estimate from reported figures, not an analyst target.

!Weak Growth (revenue 3y −73.3 %/yr)
!Thin margins · 0.0% net margin
!negative free cash flow
✓Ranks above peers (5/8)
!Narrow moat 0/100
!Evidence only low, so the estimate is less certain
Evidence: Low Range HK$0.7400 to HK$1.40

Fair value as of: Sep 11, 2026

From 1 valuation models · updated today

Fair value updated Sep 11, 2026, revised from HK$0.9000 to HK$1.12 (+24.4%) since Aug 13, 2026. Share price −12.3% over the past month.

Watch TransThera Sciences (Nanjing) for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case (HK$1.40). The favourable scenario is already priced in.
  • Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • A fairly wide model range (HK$0.7400 to HK$1.40) leaves room in how you read the outcome.

Price vs Fair Value (15 months)

HK$415.00 HK$9.10 Fair Value HK$1.12 Jun 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 11, 2026.

How to read this chart

15‑month range HK$9.10 – HK$415.00 · fair‑value band HK$0.7400 – HK$1.40 · the HK$9.46 price screens above the HK$1.12 fair value. Dashed = 300-day average. As of Sep 11, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

TransThera Sciences (Nanjing) (2617) currently trades at HK$9.46, while our model-based Fair Value estimate is HK$1.12, implying the stock looks roughly 744.6% overvalued today. The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

It earns a return on equity of −62.9%. The balance sheet holds a net cash position of HK$414M. Fundamentals as of Sep 11, 2026

Scenario range: HK$0.7400 (bear) to HK$1.40 (bull), the price of HK$9.46 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at −88%, 2617 screens richer than that median.

Fair Value models

Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
NCAV (Graham) best evidence HK$0.6700 HK$0.8900 HK$1.33 51
All 1 models by family
Asset-Based
NCAV (Graham) best evidence HK$0.6700 HK$0.8900 HK$1.33 51

Notify me when 2617 reaches fair value

Put 2617 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

EPS (TTM) HK$−0.3200
Return on equity −62.9% TTM
Return on assets (EBIT) −36.0% avg 5y
Free cash flow −HK$254M FY2025
Net cash HK$414M FY2025

Figures from reported company fundamentals · as of Sep 11, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 44/100

Of which business quality 47 · Market factors (momentum, volatility) 0

Profitability 0
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 24
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 49
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases.

Full company description

TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a multi-kinase inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors for multiple disease; and Akeso, Inc. for the treatment of hepatocellular carcinoma. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2020 – FY2025 · reported fiscal years

TransThera Sciences (Nanjing) reported revenue of 0 CNY in FY2025 versus 61.8M CNY in FY2020. Reported net income was −296M CNY in FY2025.

Growth Quality 0/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2023)
HK$1.2M
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−73.3%
Value creation/yr ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Revenue
FY20 61.8M CNY
FY22 140 CNY
FY23 1.2M CNY
FY24 0 CNY
FY25 0 CNY
Net income
FY20 −80.7M CNY
FY22 −257M CNY
FY23 −344M CNY
FY24 −275M CNY
FY25 −296M CNY

2617 screens 745% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

TransThera Sciences (Nanjing) · Fair Value
HK$1.12 −745%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "TransThera Sciences (Nanjing) Fair Value". https://www.fairvalue-calculator.com/stock/2617.HK

Peer Group

Biotechnology · 635 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation
Quality Score 47 · Above median
Profitability
Return on assets −32% · Bottom 25%
Net margin (TTM) 0% · Above median
Operating margin (TTM) 0% · Above median
Growth and dividend
Revenue growth 0% · Above median

Valuation Multiples vs Biotechnology median · lower = cheaper

P/B 1.57× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Sep 11, 2026).

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $546.12 $278.78 −49%
Regeneron Pharmaceuticals, Inc REGN $827.72 $594.40 −28%
argenx SE ARGX €877.60 €292.84 −67%
BeOne Medicines AG 688235 ¥271.00 ¥47.36 −83%
Samsung Biologics Co 207940 1,452,000 KRW 1,055,793 KRW −27%
CSL Limited CSL A$174.50 A$141.68 −19%
Alnylam Pharmaceuticals, Inc ALNY $228.61 $51.70 −77%
Royalty Pharma plc RPRX $60.58 $24.22 −60%
Celltrion, Inc 068270 190,700 KRW 74,519 KRW −61%
BioNTech SE BNTX $103.76 $45.70 −56%

Compare TransThera Sciences (Nanjing) with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Frequently asked questions

Is TransThera Sciences (Nanjing) (2617) overvalued or undervalued?
As of Sep 11, 2026, our model estimates a fair value of HK$1.12 versus a price of HK$9.46, about −88% upside (overvalued).
What is the fair value of 2617?
Our model-based fair value for TransThera Sciences (Nanjing) is HK$1.12 (as of Sep 11, 2026), built from audited fundamentals. The current price: HK$9.46.
What is the quality score of 2617?
TransThera Sciences (Nanjing) has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TransThera Sciences (Nanjing) (2617)?
Our model-based price target is the fair value of HK$1.12 (as of Sep 11, 2026) from 1 valuation models. Cautious scenario HK$0.7400, optimistic scenario HK$1.40. It is a calculation from audited fundamentals, not an analyst target.
What is the TransThera Sciences (Nanjing) stock forecast for 2026?
Our models put fair value at HK$1.12, about −88% upside versus a price of HK$9.46 (overvalued). Cautious scenario HK$0.7400, optimistic scenario HK$1.40. The calculation is refreshed regularly with new filings.
What is the net profit margin of 2617?
The net profit margin of TransThera Sciences (Nanjing) is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.
What is the intrinsic value of TransThera Sciences (Nanjing) (2617)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TransThera Sciences (Nanjing) it is HK$1.12 per share (as of Sep 11, 2026), against a price of HK$9.46. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is TransThera Sciences (Nanjing) stock overvalued or undervalued in 2026?
As of Sep 11, 2026, 2617 trades above its calculated fair value: price HK$9.46, fair value HK$1.12, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2617?
No. The price is what the market pays today (HK$9.46); the fair value is what the company's own numbers justify (HK$1.12). For TransThera Sciences (Nanjing) the two are HK$8.34 per share apart. That gap is exactly why we show both numbers side by side.
How much is TransThera Sciences (Nanjing) worth?
The market values TransThera Sciences (Nanjing) at about HK$5.1B (market capitalisation, as of Sep 11, 2026). Per share that is HK$9.46; our models calculate a fair value of HK$1.12 per share.
What do the bullish and bearish scenarios say about 2617?
Our models span a range for TransThera Sciences (Nanjing): cautious scenario HK$0.7400, base HK$1.12, optimistic HK$1.40 per share (as of Sep 11, 2026, price HK$9.46). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of TransThera Sciences (Nanjing) (2617)?
Balance-sheet figures for TransThera Sciences (Nanjing) (as of Sep 11, 2026): return on equity −62.9%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
Which stocks are comparable to TransThera Sciences (Nanjing)?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TransThera Sciences (Nanjing) stock attractive at the current price?
The data as of Sep 11, 2026: price HK$9.46, calculated fair value HK$1.12 (−88%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2617 calculated?
We run TransThera Sciences (Nanjing) through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$1.12, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 32.6 % above its aggregate fair value. TransThera Sciences (Nanjing) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on <a href="/is-it-worth-investing-now/">is it worth investing now</a>.
Free · no account needed

Watch TransThera Sciences (Nanjing) in the live analysis

One click puts TransThera Sciences (Nanjing) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.